Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
E Santoni-Rugiu, LC Melchior, EM Urbanska… - Cancers, 2019 - mdpi.com
Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
J Wang, B Wang, H Chu, Y Yao - OncoTargets and therapy, 2016 - Taylor & Francis
Identifying activating EGFR mutations is a useful predictive strategy that helps select a
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with …
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
AB Cortot, PA Jänne - European Respiratory Review, 2014 - Eur Respiratory Soc
The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …
[HTML][HTML] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F Morgillo, CM Della Corte, M Fasano, F Ciardiello - ESMO open, 2016 - Elsevier
Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …
M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
Amplification of EGFR wild-type alleles in non–small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors
S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto… - Cancer research, 2017 - AACR
EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
PS Hammerman, PA Jänne, BE Johnson - Clinical cancer research, 2009 - AACR
Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins
The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
相关搜索
- intrinsic resistance lung cancer
- egfr tyrosine acquired resistance
- kinase inhibitors acquired resistance
- cell lung cancer
- lung adenocarcinoma acquired resistance
- mechanisms of resistance lung cancer
- growth factor lung adenocarcinomas
- growth factor molecular mechanisms
- egfr mutations lung cancer
- molecular mechanisms lung adenocarcinomas
- intrinsic resistance egfr tyrosine
- intrinsic resistance kinase inhibitors
- egfr tyrosine kinase inhibitors
- intrinsic resistance egfr mutations
- egfr tyrosine lung adenocarcinoma
- lung adenocarcinoma kinase inhibitors